Home » News: BioVigilant Changes Name to Azbil BioVigilant, Inc.
News: BioVigilant Changes Name to Azbil BioVigilant, Inc.
BioVigilant Systems, Inc., inventors of Instantaneous Microbial Detection, announced today that it has changed its name to Azbil BioVigilant, Inc. The name change reflects the Company’s alignment with its corporate parent, Yamatake Corporation of the azbil Group, to focus its 47 subsidiaries and affiliates around a common philosophy of “human-centered automation.”
“Since Yamatake’s formation in 1906, the company has not wavered in its focus to create and deliver value to society. It is this longstanding view that drives the philosophy bringing together the many family members now comprising the azbil Group. Azbil BioVigilant’s mission - to pioneer innovative technology that elevates the level of quality assurance and productivity achievable in controlled manufacturing environments - is a natural fit with this philosophy,” said Aric Meares, President and CEO of Azbil BioVigilant. He added, “With the resources of a 105-year-old company with over 8000 employees and FY2010 revenues approaching $3 billion dollars (219.2 billion yen), our mission objectives are well supported.”
In May 2009, Yamatake Corporation acquired the majority stock of BioVigilant, extending its expertise in automation which includes a growing portfolio of products and solutions organized into Building Automation, Advanced Automation and Life Automation business units. Collectively, azbil Group companies create value for customers and society in environmental preservation and energy conservation, health and safety, quality of life, and human productivity. Effective April 1, 2012, Yamatake Corporation also will transition to the new corporate name of Azbil Corporation.
About Azbil BioVigilant
With headquarters in Tucson, Arizona, Azbil BioVigilant invented instantaneous microbial detection technology to address environmental monitoring needs in the pharmaceutical, biotechnology, healthcare, and environmental applications. Azbil BioVigilant’s IMD systems detect - instantaneously and in real time - particle count, size, and biological status. Unlike other rapid microbial methods, Azbil BioVigilant’s optically-based systems require no staining, no reagents, no waiting period, and little human intervention. The company holds 19 patents with an additional 37 applications pending. BioVigilant’s parent company is Yamatake Corporation of the azbil Group, part of the TOPIX Mid400 traded on the Tokyo Stock Exchange. For more information, go to www.biovigilant.com.
Merck Stops Development of Parkinson’s DrugFrom Bloomberg
Merck & Co. will end development of preladenant because a preliminary review of late-stage clinical trials suggests it doesn’t work
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
- All news »